NY-ESO-1 specific TCR-HEK293 cell line
CAT:
716-CHEK-STP114-2Vials
Size:
2 Vials
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: Yes
NY-ESO-1 specific TCR-HEK293 cell line
- Background: NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. This cell can specifically recognize HLA-A2/NY-ESO-1.
- Description: NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. This cell can specifically recognize HLA-A2/NY-ESO-1.
- Host: HEK 293
- Origin Species: Human
- Target: NY-ESO-1
- Tag: Native
- Applications: Binding assay by FACS and cell based ELISA.
- Format: Liquid
- Shipping Conditions: Dry ice
- Storage Conditions: Frozen in liquid nitrogen